Trial Profile
A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Efficacy, and Pharmacokinetics of the Fixed Combination of AGN-199201 and AGN-190584 in Patients With Presbyopia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2020
Price :
$35
*
At a glance
- Drugs Oxymetazoline (Primary) ; Pilocarpine (Primary)
- Indications Presbyopia
- Focus Therapeutic Use
- Sponsors Allergan
- 15 Nov 2017 Status changed from active, no longer recruiting to completed.
- 04 Oct 2017 Planned End Date changed from 4 Jan 2018 to 27 Oct 2017.
- 04 Oct 2017 Planned primary completion date changed from 4 Jan 2018 to 27 Oct 2017.